▼Gemcitabine for lung cancer. Issue 9 (September 1996)

• Record Type: Journal Article
• Is Part Of: Drug and therapeutics bulletin. Volume 34:Issue 9(1996)
• Page Start: 71
• Page End: 72
• Publication Date: 1996-09
• Subjects: Drugs -- Periodicals; Therapeutics -- Periodicals; Pharmacology -- Periodicals; 615.5
• DOI: 10.1136/dtb.1996.34971
• Languages: English
• ISSNs: 1755-5248

Abstract

Abstract : The prognosis for most patients with lung cancer is poor. About 75% will have tumours of non-small-cell lung cancer (NSCLC) type and, at diagnosis, 4 out of 5 patients with NSCLC have either locally advanced or metastatic disease. Despite treatment, fewer than 1 in 10 of these people will be alive 5 years later. Gemcitabine (Gemzar - Lilly) has recently been licensed for the palliative treatment of adults with such late-stage cancers. It is promoted as a "new option in the management of NSCLC" with "no trade off between tumour remission and toxicity". What advantages does gemcitabine offer?